U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07708038) titled 'Anti-Interleukin-6 (IL6) in Calciphylaxis' on July 13.
Brief Summary: Calciphylaxis is a rare but incredibly dangerous condition that causes small blood vessels in the skin to become blocked by calcium buildup and blood clots. This leads to painful skin sores (necrosis) that do not heal easily. Because these open wounds are prone to severe infections, the outlook for patients is often grim; more than half of those diagnosed do not survive past the first year. Currently, there are no Food and Drug Administration (FDA) approved medications specifically designed to stop the progression of this disease. However, recent research has iden...